Frontiers in Immunology (Sep 2022)

The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population

  • Aravinthan Loganathan,
  • Aravinthan Loganathan,
  • Fionnuala McMorrow,
  • Hui Lu,
  • Danyang Li,
  • Ben Mulhearn,
  • Ben Mulhearn,
  • Neil John McHugh,
  • Sarah Louise Tansley,
  • Sarah Louise Tansley

DOI
https://doi.org/10.3389/fimmu.2022.975939
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundThe reliable detection of myositis-specific autoantibodies (MSA) provides valuable clinical information regarding prognosis, clinical progression and diagnostic confirmation.ObjectivesTo evaluate the reliability of a commercial ELISA immunoassay in detecting myositis-specific autoantibodies in comparison to immunoprecipitation as the reference standard.MethodsSerum samples were chosen from a biobank of more than 3000 samples. Samples with a confirmed MSA on Immunoprecipitation (n=116) were evaluated in duplicate by ELISA to detect Mi2, MDA5, Jo1, EJ, KS, PL-7 and PL-12 (Medical & Biological Laboratories Co. Ltd, Nagoya, Aichi, Japan). Healthy control samples (n=246) confirmed autoantibody negative by immunoprecipitation were similarly assessed.ResultsThere was a very good agreement between ELISA and immunoprecipitation for serum samples containing anti-Mi2, MDA5, Jo1, EJ, KS and PL-7 and PL-12 auto-antibodies. Cohen’s κ values ranged from 0.86-1 for the measured autoantibodies on ELISA.ConclusionELISA was an accurate method for detecting anti-synthetase, anti-Mi2 and anti-MDA5 autoantibodies.

Keywords